How to preserve your health? How to find it? And to what extent can we really own it? These key questions are at the heart of the sixth edition of our annual Futurapolis Santé meeting, which will take place on 7 and 8 October at the Opéra Comédie in Montpellier and where entrepreneurs, leading healthcare professionals and renowned researchers meet to answer. On the program: local medicine, personalized treatment path, physical activity, digital … But also expert advice to ensure your longevity … in good health!
Find all the conferences of the event here as well as on our social networks (Facebook, Twitter, Daily movement).
12:05 – Hacking in the hospital: the war of health data is underway
On 21 August 2022 it will remain in the memory of all the staff of the Corbeil-Essonne hospital: a cyber attack, with a ransom demand, has completely destabilized its computer network. Patients will remember it too, whether they have been able to stay in the facility or have to be relocated. How can hospitals protect themselves from such practices? And how to protect the health data of the patients who visit them? Because our health data can be resold at a high, very high price … The demand today is tormenting everyone’s mind.
With Vincent Templarresponsible for the security of the information system of the CHU and the GHT Est Hérault – Sud Aveyron and the data protection officer of the GHT Est Hérault – Sud Aveyron, and Laurent Wilmann-Courteaudirector of the digital health and data protection division of the university hospital of Montpellier.
11h 45 – Microbiome: how?
“It is an ecosystem, a set of living microorganisms, made up of bacteria, fungi and viruses. This is one million microorganisms per cm2 on your skin. It is of a thousand species, therefore a great diversity that is defined differently depending on where it is found on the skin, we could almost speak of “microbiota” in the plural “, he explains to our audience. Magali Moreauhead of the microbiome laboratories in L’Oréal research.
11h 30 – The skin microbiome, a beneficial shield
Less well known than the microbiota that lines the inside of our intestines, the skin microbiome is also made up of the billions of microorganisms that live on the surface and inside our skin. As far as our digestive system is concerned, this flora represents a strong ally. These bacteria and fungi act as an invisible shield to the naked eye against allergens, pollutants, and other substances that are harmful to the skin’s lining. They are also against the installation of “bad” microbes. As for the intestinal flora, the skin microbiome is formed from birth, it is unique and evolves according to age, sex and lifestyle. And it is recommended to take care of it. Cosmetic specialists have understood this well and take this into account in their research.
With Magali Moreauhead of the microbiome laboratories in L’Oréal research e Cristina BodemerHead of the Department of Dermatology at Necker Hospital and Professor of Dermatology at the University of Paris.
11h 21 – On the causes of autism
For a long time, “we had very little support for children and adults with autism spectrum disorders because we had a very misconception of the causes of this disorder,” he recalls. Claire Mate, inter-ministerial delegate responsible for the implementation of the national strategy for autism. We thought in particular that he was tied to the attitudes of the parents, especially the mothers.
11h 15 – Neurodevelopmental disorders: the numbers
“Neurodevelopmental disorders (autism, DYS, ADHD, etc.) are progressing significantly and affect between 12 and 15% of births in France. We are therefore reaching very high levels, ”he explains Claire Mateinter-ministerial delegate responsible for the implementation of the national strategy for autism.
10h45 – The origins of autism
The abandonment of the psychoanalytic vision, followed by a very early treatment even before the diagnosis was formalized, has allowed real progress to children suffering from neurodevelopmental disorders, in particular of the autism spectrum. This was the focus of the autism plan launched in 2018. As of July 1, 30,000 young people under the age of 7 had been identified as having a neurodevelopmental disorder and treated. At the same time, researchers are mobilizing to try to discover the causes of the problem by participating in the MARIANNE study: 2,300 families, parents and children, will be followed to determine the role of environmental and biological factors. Answer in 10 years.
With Amaria Bagdadlihead of the Center of Excellence on Autism and Neurodevelopmental Disorders – CeAND (CHU and University of Montpellier) and researcher at the Center for Research in Epidemiology and Population Health (CESP) in Inserm, Claire Mateinter-ministerial delegate responsible for the implementation of the national strategy for autism e Sabrina Philippon Kouidermother of two young children with autism.
10:32 – Rare diseases: the importance of cooperation
“We will not be able to structure ourselves if we do not join forces, this is the logic of an extremely close-knit community between care, research and public policies. Faced with the complexity of rare diseases, we need to structure ourselves, it took time. After HIV, we had a structuring of the movement, with patient associations and thanks in particular to Simone Veil who stimulated this reflection “, says Anne-Sophie Lapointeproject manager for rare diseases, Directorate General of Health, French Ministry of Health.
10:00 – Rare diseases and research
A disease is said to be rare when it affects less than one in 2000 births. That’s not much. But due to the large number of existing pathologies, 3 million people are directly affected in France. Many families experience misdiagnosis, lack of care, and daily difficulties. Because alongside the more well-known ones such as cystic fibrosis or myopathies, other diseases affect only a few cases in the world. And there is currently no cure for 95% of these conditions. However, thanks to the intense research activity carried out, knowledge is advancing for these people and sometimes it has positive repercussions for patients suffering from other diseases.
With Franck CousseransGeneral Manager France of Jazz Pharmaceuticals, Yves Dauvilliersprofessor of neurology and physiology, head of the sleep laboratory at the neurology department of the university hospital of Montpellier and specialist in narcolepsy, and Anne-Sophie Lapointeresponsible for the rare diseases project at the Directorate General of Health (Ministry of Health).
